Fecal microbiome changes and specific anti-bacterial response in patients with ibd during anti-tnf therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F21%3A00551610" target="_blank" >RIV/61388971:_____/21:00551610 - isvavai.cz</a>
Alternative codes found
RIV/00023001:_____/21:00081909 RIV/00216208:11110/21:10434244 RIV/00064211:_____/21:W0000004 RIV/00216208:11130/21:10434244
Result on the web
<a href="https://www.mdpi.com/2073-4409/10/11/3188" target="_blank" >https://www.mdpi.com/2073-4409/10/11/3188</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cells10113188" target="_blank" >10.3390/cells10113188</a>
Alternative languages
Result language
angličtina
Original language name
Fecal microbiome changes and specific anti-bacterial response in patients with ibd during anti-tnf therapy
Original language description
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn’s disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
10606 - Microbiology
Result continuities
Project
<a href="/en/project/NV18-09-00493" target="_blank" >NV18-09-00493: Microbiota as a biomarker for prediction of mucocutaneous adverse effects of biologics used in inflammatory bowel disease</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cells
ISSN
2073-4409
e-ISSN
2073-4409
Volume of the periodical
10
Issue of the periodical within the volume
11
Country of publishing house
CH - SWITZERLAND
Number of pages
21
Pages from-to
3188
UT code for WoS article
000749993600001
EID of the result in the Scopus database
2-s2.0-85118973464